Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1001233/000162828023008516/sgmo-20230313.htm
March 2023
March 2023
March 2023
March 2023
February 2023
December 2022
December 2022
December 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1001233/000162828023008516/sgmo-20230313.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Ticker: SGMOEvents:
CIK: 1001233
Form Type: 8-K Corporate News
Accession Number: 0001628280-23-008516
Submitted to the SEC: Fri Mar 17 2023 5:14:21 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Monday, March 13, 2023
Industry: Biological Products No Disgnostic Substances